Our History
We have a proven track record of efficient and consistent achievement.
Our company was founded in 2017 with the goal of developing novel therapeutics to transform the lives of people living with serious metabolic diseases. Our rapid progress and history of achieving critical milestones culminated in our acquisition by Novo Nordisk, a company with an established history in developing innovative treatments for chronic metabolic disease.
SYMMETRY Phase 2b week 96 readout reported fibrosis improvement with EFX in participants with MASH and compensated cirrhosis (F4c) at Week 96, as well as improvements in MASH and other markers of cardiometabolic disease
Acquisition by Novo Nordisk
Novo Nordisk completed its acquisition of Akero Therapeutics, adding EFX to the company’s portfolio of treatment options across the stages of MASH and embodying Novo Nordisk’s commitment to address the unmet medical needs of people with MASH and other serious metabolic disease
HARMONY Phase 2b week 96 study readout demonstrated statistically significant improvements in fibrosis and MASH at Week 96 in participants with noncirrhotic MASH and moderate to advanced fibrosis (F2/F3)
Public follow-on offering with gross proceeds of approximately $366.9M
Public offering of $334.8M in net proceeds raised
SYMMETRY Phase 2b Expansion Cohort D readout showed that adding EFX to GLP-1 receptor agonists was generally well tolerated, reduced liver fat, and improved noninvasive markers of fibrosis in participants with MASH and type 2 diabetes
SYMMETRY Phase 2b week 36 readout demonstrated that in participants with MASH and compensated cirrhosis (F4c), treatment with EFX for 36 weeks resulted in a nonsignificant trend for improved fibrosis, statistically significant improvements in MASH, and improvements in markers of liver injury, fibrosis, insulin sensitivity, and lipids
Phase 3 SYMMETRY Program initiated and dosed the first participants in two parallel, randomized, placebo-controlled Phase 3 trials: SYNCHRONY Histology (designed to evaluate the efficacy and safety of EFX in people with biopsy-defined noncirrhotic MASH and moderate to advanced fibrosis (F2/F3), and SYNCHRONY Real-World (designed to evaluate the safety and tolerability of EFX in people with MASH or metabolic dysfunction-associated steatotic liver disease (MASLD))
HARMONY Phase 2b study readout showed statistically significant improvements with EFX in fibrosis and MASH after 24 weeks in people with MASH with moderate or advanced fibrosis (F2/F3)
Upsized public follow-on offering with gross proceeds of approximately $230M
FDA breakthrough therapy designation for lead candidate EFX for the treatment of MASH
